Tim Smith

This new research suggests a potential need for policymakers to examine nursing home regulations related to staffing and to collaborate with administrators to create better policies.

In this recent analysis of hyperhidrosis burden on patients, prevalence of the condition and its impacts on patients demonstrate the value of exploring knowledge gaps for this disease.

This analysis of Medicare beneficiaries over age 71 suggests the importance of discrete severity measures of hearing loss in older adults, as opposed to binary hearing loss terminology.

This interview segment with Dr. Kidon featured a discussion about her views on current research in the immunotherapy and food allergy space, as well as her views on the future.

Dr. Kidon spoke in this interview segment regarding a recent immunotherapy product she and her team have been focused on for patients with peanut allergies.

This interview with Dr. Kidon featured a discussion regarding Kidon’s current peanut allergy research and views on recent developments in the field.

This new phase 4 data provides some valuable insights for healthcare professionals and those seeking to compare therapy options for psoriasis.

This data on a large racial and ethnic minority cohort indicated that low melanoma incidence and detection rates and more aggressive nature of cancer shows the need for greater attention.

This new research highlights the value of habit replacement intervention, supported by the fact that apparent low usefulness/efficacy of other methods for patients can often manifest in poorer retention.

This new data on younger acute sinusitis patients may indicate the value of testing for specific bacteria at the time of presentation in order to lower the use of antibiotics for this condition.

This new research examined trends among adults with severe and recurrent anaphylaxis, and identified several major risk factors.

This new research is the first to examine the use of the iMAP milk ladder in primary care settings for younger patients with IgE-mediated cow’s milk protein allergy.

This new data highlights the importance of enhancing social connection for older adults and identifying those at greater risk of nursing home entry.

This new research showed the value of physical exercise as well as training to help prevent cognitive declines, although the results had some inconsistencies.

In this interview with Dr. Baldwin, she spoke on her team’s recent research and its application to rosacea and other dermatologic conditions.

The long-awaited approval for VP-102 makes this treatment the first available therapy for the pox virus-borne skin disease.

New late-breaking trial data from the ADhere, Adjoin, ADvocate1, and ADvocate2 trials showed solid results for lebrikizumab in treating moderate-to-severe atopic dermatitis.

This new data could be valuable for follow-up appointments with patients who have cutaneous squamous cell carcinoma and for skin cancer services.

This new data on factors which may inhibit access to dermatologic care indicates the potential value for policy-makers as well as educators to make changes to fill such gaps in care.

This study indicates that interactions between genetic risk and lifestyle decisions among adults in China could allow for direction in prevention of early-stage dementia.

In his interview, Dr. Amin discusses his views on the FDA’s recent approval of ritlecitinib for the treatment of adolescent patients with alopecia areata.

For this segment of her interview, Dr. Mellerio further discussed the contents of her talk on new treatment options for epidermolysis bullosa, highlighting DEB and EB simplex.

In this interview segment, Dr. Mellerio spoke about the contents of her presentation titled ‘New Treatment Approaches for Epidermolysis Bullosa.’

This new data indicates that while it is not a physically limiting disease, alopecia areata can substantially affect patients’ lives on an individual and national level.

This new data highlights the need to address certain sociocultural, socioeconomic, and environmental factors that can more strongly affect individuals in minority groups.

The study’s findings bring major lessons for dermatologists to light, the most apparent of which being that many reasons for discordance between clinicians and patients may be modified.

These new findings may lead to a more accessible and rigorous approach to diagnosis, with a possibility of reduction of over-diagnosis.

This segment of her interview with HCPLive featured a discussion with Ferris on the FRONTIER 1 phase 2b trial results and their implications for psoriasis patients.

New phase 2b data from the FRONTIER 1 study showed promise for what could become the first and only oral IL-23 antagonist peptide for psoriasis.

While the unmet needs of patients of color is a growing concern in the dermatology world, more has to be done to address the obvious disparities in care.